Limits...
Aberrant over-expression of TRPM7 ion channels in pancreatic cancer: required for cancer cell invasion and implicated in tumor growth and metastasis.

Yee NS, Kazi AA, Li Q, Yang Z, Berg A, Yee RK - Biol Open (2015)

Bottom Line: Anti-TRPM7 immunoreactivity in pancreatic adenocarcinoma significantly correlates with the size and stages of tumors.In human pancreatic adenocarcinoma cells in which TRPM7 is highly expressed, short hairpin RNA-mediated suppression of TRPM7 impairs cell invasion.The results demonstrate that TRPM7 channels are over-expressed in a proportion of the pre-malignant lesions and malignant tumors of the pancreas, and they are necessary for invasion by pancreatic cancer cells.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology-Oncology, Department of Medicine, Penn State College of Medicine, Program of Experimental Therapeutics, Penn State Hershey Cancer Institute, Penn State Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA 17033, USA nyee@hmc.psu.edu.

No MeSH data available.


Related in: MedlinePlus

Immunohistochemical analysis of TRPM7 in malignant pancreatic tumors.(A,B) Adenocarcinoma. (C,D) Adenosquamous carcinoma. (E,F) Solid pseudopapillary neoplasm. (G,H) Acinar cell carcinoma. (I,J) Neuroendocrine tumor. H&E, original magnification ×200 (A,C,E,G,I). Immunohistochemistry using anti-TRPM7 antibodies, original magnification ×400 (B,D,F,H,J).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4400593&req=5

f02: Immunohistochemical analysis of TRPM7 in malignant pancreatic tumors.(A,B) Adenocarcinoma. (C,D) Adenosquamous carcinoma. (E,F) Solid pseudopapillary neoplasm. (G,H) Acinar cell carcinoma. (I,J) Neuroendocrine tumor. H&E, original magnification ×200 (A,C,E,G,I). Immunohistochemistry using anti-TRPM7 antibodies, original magnification ×400 (B,D,F,H,J).

Mentions: Anti-TRPM7 immunoreactivity was examined in pancreatic adenocarcinoma, adenosquamous carcinoma, solid pseudopapillary neoplasm, acinar cell carcinoma, and neuroendocrine tumor. TRPM7 is expressed at a moderate to high level in the majority of pancreatic adenocarcinoma cases (Fig. 2A,B). Notably, anti-TRPM7 immunoreactivity in pancreatic adenocarcinoma is accentuated towards the plasma membrane (Fig. 2B). In pancreatic adenosquamous carcinoma and solid pseudopapillary neoplasm, TRPM7 is expressed at low to moderate levels (Fig. 2C–F). In contrast to normal pancreatic acinar cells, which have no appreciable expression of TRPM7 (Fig. 1A), there is moderate anti-TRPM7 immunoreactivity in all cases of acinar cell carcinoma examined (Fig. 2G,H). In pancreatic neuroendocrine tumors, moderate to high expression of TRPM7 was identified (Fig. 2I,J). For each histological type of pancreatic tumor, the proportions of samples with corresponding TRPM7 expression levels are described in Table 1. These data suggest that TRPM7 is aberrantly over-expressed in various types of malignant pancreatic neoplasms.


Aberrant over-expression of TRPM7 ion channels in pancreatic cancer: required for cancer cell invasion and implicated in tumor growth and metastasis.

Yee NS, Kazi AA, Li Q, Yang Z, Berg A, Yee RK - Biol Open (2015)

Immunohistochemical analysis of TRPM7 in malignant pancreatic tumors.(A,B) Adenocarcinoma. (C,D) Adenosquamous carcinoma. (E,F) Solid pseudopapillary neoplasm. (G,H) Acinar cell carcinoma. (I,J) Neuroendocrine tumor. H&E, original magnification ×200 (A,C,E,G,I). Immunohistochemistry using anti-TRPM7 antibodies, original magnification ×400 (B,D,F,H,J).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4400593&req=5

f02: Immunohistochemical analysis of TRPM7 in malignant pancreatic tumors.(A,B) Adenocarcinoma. (C,D) Adenosquamous carcinoma. (E,F) Solid pseudopapillary neoplasm. (G,H) Acinar cell carcinoma. (I,J) Neuroendocrine tumor. H&E, original magnification ×200 (A,C,E,G,I). Immunohistochemistry using anti-TRPM7 antibodies, original magnification ×400 (B,D,F,H,J).
Mentions: Anti-TRPM7 immunoreactivity was examined in pancreatic adenocarcinoma, adenosquamous carcinoma, solid pseudopapillary neoplasm, acinar cell carcinoma, and neuroendocrine tumor. TRPM7 is expressed at a moderate to high level in the majority of pancreatic adenocarcinoma cases (Fig. 2A,B). Notably, anti-TRPM7 immunoreactivity in pancreatic adenocarcinoma is accentuated towards the plasma membrane (Fig. 2B). In pancreatic adenosquamous carcinoma and solid pseudopapillary neoplasm, TRPM7 is expressed at low to moderate levels (Fig. 2C–F). In contrast to normal pancreatic acinar cells, which have no appreciable expression of TRPM7 (Fig. 1A), there is moderate anti-TRPM7 immunoreactivity in all cases of acinar cell carcinoma examined (Fig. 2G,H). In pancreatic neuroendocrine tumors, moderate to high expression of TRPM7 was identified (Fig. 2I,J). For each histological type of pancreatic tumor, the proportions of samples with corresponding TRPM7 expression levels are described in Table 1. These data suggest that TRPM7 is aberrantly over-expressed in various types of malignant pancreatic neoplasms.

Bottom Line: Anti-TRPM7 immunoreactivity in pancreatic adenocarcinoma significantly correlates with the size and stages of tumors.In human pancreatic adenocarcinoma cells in which TRPM7 is highly expressed, short hairpin RNA-mediated suppression of TRPM7 impairs cell invasion.The results demonstrate that TRPM7 channels are over-expressed in a proportion of the pre-malignant lesions and malignant tumors of the pancreas, and they are necessary for invasion by pancreatic cancer cells.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology-Oncology, Department of Medicine, Penn State College of Medicine, Program of Experimental Therapeutics, Penn State Hershey Cancer Institute, Penn State Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA 17033, USA nyee@hmc.psu.edu.

No MeSH data available.


Related in: MedlinePlus